US10342845B1 - Diabetic nutritional composition - Google Patents

Diabetic nutritional composition Download PDF

Info

Publication number
US10342845B1
US10342845B1 US15/355,490 US201615355490A US10342845B1 US 10342845 B1 US10342845 B1 US 10342845B1 US 201615355490 A US201615355490 A US 201615355490A US 10342845 B1 US10342845 B1 US 10342845B1
Authority
US
United States
Prior art keywords
mcg
nutritional composition
vitamin
composition further
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US15/355,490
Inventor
Houn Simon Hsia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US15/355,490 priority Critical patent/US10342845B1/en
Application granted granted Critical
Publication of US10342845B1 publication Critical patent/US10342845B1/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A61K36/8998—Hordeum (barley)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/733—Fructosans, e.g. inulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/42—Cucurbitaceae (Cucumber family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to nutritional compositions useful for treatment of the diabetic condition in humans.
  • Diabetes is one of the most deadly diseases of all centuries. Preventing and treatment of diabetes, therefore, and extremely important endeavor for centuries to pursue. Much progress has been made over the last 50 years for the treatment of diabetes, including dietary understanding of the disease, as well as a number of drug therapies. A major shortcoming of these therapeutic treatments is their harmful effects to the human system since, in many cases, the practice of such therapies causes the subject harm.
  • a healthy and potent human immune system and human endocrine system are salient to prevent and remediate the effects of the diabetic conditions.
  • the preset invention overcomes many of the shortcomings of the prior art in connection with the preventative and remedial treatments of the diabetic human condition by providing compositions that work together in a synergistic manner, to enhance the endocrine system; and more specifically to prevent or slow down complications characteristic of the human diabetic condition.
  • the present invention provides nutritional compositions as powders, lozenges, tablets or liquids, that are employed as oral supplementation to the human diet.
  • the compositions of the present invention provide for supplementation to the diet of the human system, and specifically for those humans predisposed to, or suffering from, the diabetic human condition.
  • compositions that when injested support the human endocrine system.
  • the present invention teaches a combination of specific nutrition's suitable for oral consumption by the human body.
  • the compositions of the present invention when orally ingested on a daily basis, in combination with or without therapeutic treatments for diabetes, work to aid the diabetic patient in slowing or eliminating, or reversing the progression of the disease.
  • compositions of the present invention are not well understood, many cases have been reported of diabetic patients benefiting from the use of the present invention.
  • compositions include as preferred essential component the mineral of chromium.
  • the preferred form of chromium is yeast.
  • the preferred amount of chromium yeast is from about 5 mcg to about 5000 mcg, and more preferred between about 100 meg to about 2500 mcg, and most preferably from between 1000 mcg to about 2000 mcg.
  • the preferred chromium yeast strains are Saccharomyces cerevisiae, Saccharomyces exiguous, Saccharomyces pastorianus, Saccharomyces boulardii, Saccharomyces bayanus, Saccharomyces eubayanus, Saccharomyces florentinus, Saccharomyces fragilis.
  • a prime essential ingredient included in all the embodiments of the present invention is Green Barley Juice powder.
  • the preferred form of Green Barley Juice powder is derived from organic barley and through the process of lylyophilization of the extracted juice of the organic barley.
  • the amount of Green Barley Juice powder 500 mg to about 3500 mg, more preferably from between 750 mg to about 2000 mg, and most preferably between 800 mg to about 1500 mg.
  • Inulin must be included as an essential component of the present invention.
  • the types of Inulin to be used in the present invention include short chain, medium chain, and long chain polymers of fructoligosaccharides.
  • the preferred amount in the present invention is from about 0.5 g to about 10.0 grams, preferably between 1 g and 7.5 g, and most preferably between 2 g and 5 g.
  • the preferred amount of Bitter Melon is from about 2 mg to about 300 mg, preferably from about 50 mg to about 250 mg, and most preferably about 100 mg to about 175 mg.
  • Erythritol Another essential component is Erythritol.
  • the preferred amount of Erythritol is between 1 g and 30 g, most preferably between from about 2 g-14 g.
  • Fenugreek Seed Another essential component is Fenugreek Seed.
  • the preferred amount of Fenugreek Seed is from about 2 mg to about 200 mg, preferably from about 50 mg to about 250 mg, and most preferably about 75 mg to about 125 mg
  • Citrus Bioflavonoid Another essential component is Citrus Bioflavonoid.
  • the preferred amount of Citrus Bioflavonoid is from about 2 mg to about 300 mg, preferably from about 50 mg to about 250 mg, and most preferably about 100 mg to about 175 mg
  • Lime Juice Powder Another essential component is Lime Juice Powder.
  • the preferred amount of Lime Juice Powder is from about 1 mg to about 100 mg, preferably from about 50 mg to about 250 mg, and most preferably about 10 mg to about 75 mg.
  • Wheat Grass Juice Powder Another essential component is Wheat Grass Juice Powder.
  • the preferred amount of Wheat Grass Juice Powder is from about 0.5 mg to about 500 mg, preferably from about 50 mg to about 350 mg, and most preferably about 100 mg to about 275 mg
  • compositions may also include as preferred component the mineral of selenium.
  • the preferred form of selenium is selenium yeast.
  • the preferred amount of selenium yeast is from about 5 mcg to about 5000 mcg, and more preferred between about 100 mcg to about 2500 mcg, and most preferably from between 1000 mcg to about 2000 mcg.
  • the preferred selenium yeast are Saccharomyces cerevisiae, Saccharomyces exiguous, Saccharomyces pastorianus, Saccharomyces boulardii, Saccharomyces bayanus, Saccharomyces eubayanus, Saccharomyces florentinus, Saccharomyces fragilis.
  • Beta Carotene Another essential component of the present invention is Beta Carotene.
  • the preferred form of beta carotene is the naturally occurring form.
  • the preferred amount is between 10 mcg and 100 mg, and more preferably between 100 mcg and 10 mg, and most preferably between about 500 mcg and 50 mg.
  • Vitamin D3 may be added to the nutritional compositions of the present invention.
  • the preferred form of Vitamin D3 is Cholecalciferol.
  • the preferred amount of Vitamin D3 is from between 50 iu and 3000 iu, and more preferably between from about 70 iu to about 500 iu, and most preferably from about 100 iu to about 250 iu.
  • Vitamin K Another prime nutrient that may be included in the embodiments of the present invention is Vitamin K.
  • the preferred form of Vitamin K is Phytonadione.
  • the preferred amount of Vitamin K is between 2.5 mcg to about 250 mcg, more preferably from between 15 mcg to about 100 mcg, and most preferably between 20 mcg to about 75 mcg.
  • Vitamin B6 Another nutrient important to the efficacy of the present invention is Vitamin B6.
  • the preferred form of Vitamin B6 is Pyridoxine hydrochloride.
  • the preferred amount is between 0.1 mg to about 100 mg, most preferably between about 0.5 mg to about 25 mg, and most preferably from about 0.75 mg to about 10 mg.
  • Vitamin B12 may be included in the present invention.
  • the preferred form of Vitamin B12 is Cyanocobalamin.
  • the preferred amount of Vitamin B12 is between about 0.3 mcg to about 900 mcg, most preferably between about 0.75 mcg to about 50 mcg, and most preferably between 1 mcg and 10 mcg.
  • Folic Acid Another nutrient that is important to the present invention is Folic Acid.
  • the preferred amount of Folic Acid is between about 25 mcg to about 1000 mcg, most preferably between about 100 mcg to about 750 mcg, and most preferably between 200 mcg and 400 mcg.
  • the mineral Zinc is important to include in the present invention.
  • the preferred amount of Zinc is between about 0.65 mcg to about 4000 mcg, most preferably between about 1 mcg to about 400 mcg, and most preferably between 3 mcg and 50 mcg.
  • the mineral Molybdenum is important to include in the present invention.
  • the preferred form of Molybdenum is from yeast.
  • the preferred amount of Molybdenum is between about 2.5 mcg to about 1000 mcg, most preferably between about 10 mcg to about 130 mcg, and most preferably between 15 mcg and 60 mcg.
  • Coenzyme Q-10 Another important nutrient is Coenzyme Q-10.
  • the preferred amount of Coenzyme Q-10 is from about 30 mg to about 1000 mg, most preferably from between about 50 mg to 300 mg, and most preferably between about 60 mg to about 180 mg.
  • the above ingredients were admixed as a single serving, and were blended together and shaken until homogeneous blend was obtained.
  • the blended composition was poured into 250 mL of water, mixed and then consumed via drinking.
  • the above ingredients were admixed as a single serving, and were blended together and shaken until homogeneous blend was obtained.
  • the blended composition was poured into 250 mL of water, mixed and then consumed via drinking.
  • the above ingredients were admixed as a single serving, and were blended together and shaken until homogeneous blend was obtained.
  • the blended composition was poured into 250 mL of water, mixed and then consumed via drinking.
  • the above ingredients were admixed as a single serving, and were blended together and shaken until homogeneous blend was obtained.
  • the blended composition was poured into 250 mL of water, mixed and then consumed via drinking.
  • Barley Grass Juice Powder 2550 mg Inulin 850 mg Chromium (from Chromium Yeast) 1200 mcg Bitter Melon Fruit 200 mg Fenugreek Seed 39 mg Citrus Bioflavonoid 80 mg Lime Juice Powder 90 mg Wheat Grass Juice Powder 90 mg Fish Oil 310 mg Selenium (from Selenium yeast) 500 mcg Beta Carotene 100 mcg Ascorbic Acid 500 mg Vitamin D3 100 iu Vitamin K 15 mcg Vitamin B6 0.5 mg Vitamin B12 1 mcg Folic Acid 250 mcg Zinc 5.3 mg Molybdenum 15 mcg CoQ-10 52 mg Niacin 3.1 mg Riboflavin 300 mcg Thiamin 130 mcg Erythritol 2500 mg Biotin 1 mg Calcium 400 mg Iron 3 mg Phosphourous 220 mg Iodine 37 mg Copper 510 mcg Manganese 524 mcg Inositol
  • the above ingredients were admixed as a single serving, and were blended together and shaken until homogeneous blend was obtained.
  • the blended composition was poured into 250 mL of water, mixed and then consumed via drinking.

Abstract

The present invention provides nutritional compositions as powders, lozenges, tablets or liquids that are employed as oral supplementation to the human diet. The compositions of the present invention provide for supplementation to the diet of the human system, and specifically for those humans predisposed to, or suffering from, the diabetic human condition. It is believed that the key ingredients of the present invention work synergistically together to aid in the slowing, stopping, or reversing the symptoms and metabolic disorder characteristic of the human diabetic condition. These essential components are comprised of uniquely-selected minerals, phytonutrients and vitamin combinations.

Description

FIELD OF THE INVENTION
The present invention relates to nutritional compositions useful for treatment of the diabetic condition in humans.
BACKGROUND OF THE INVENTION
Diabetes is one of the most deadly diseases of all mankind. Preventing and treatment of diabetes, therefore, and extremely important endeavor for mankind to pursue. Much progress has been made over the last 50 years for the treatment of diabetes, including dietary understanding of the disease, as well as a number of drug therapies. A major shortcoming of these therapeutic treatments is their harmful effects to the human system since, in many cases, the practice of such therapies causes the subject harm.
A healthy and potent human immune system and human endocrine system are salient to prevent and remediate the effects of the diabetic conditions. The preset invention overcomes many of the shortcomings of the prior art in connection with the preventative and remedial treatments of the diabetic human condition by providing compositions that work together in a synergistic manner, to enhance the endocrine system; and more specifically to prevent or slow down complications characteristic of the human diabetic condition.
SUMMARY OF THE INVENTION
The present invention provides nutritional compositions as powders, lozenges, tablets or liquids, that are employed as oral supplementation to the human diet. The compositions of the present invention provide for supplementation to the diet of the human system, and specifically for those humans predisposed to, or suffering from, the diabetic human condition.
It is the prime objective of the present invention to provide nutritive compositions that provide for an increased activity in combating the human diabetic condition.
It is another objective of the present invention to provide for compositions to treat the diabetic human condition, and help to reverse the symptoms of the diabetic condition.
It is another objective of the present invention to provide for compositions to prevent the diabetic human condition, and help to inhibit the diabetic human condition from progressing to a more harmful diabetes condition.
It is another objective of the present invention to provide for specific forms of certain active components.
It is another objective of the present invention to provide for compositions that help inhibit the progression of diabetis.
It the prime objective of the present invention to provide for compositions that when injested support the human endocrine system.
It is a further objective of the present invention to normalize carbohydrate metabolism.
DETAILED DESCRIPTION OF THE INVENTION
The present invention teaches a combination of specific nutrition's suitable for oral consumption by the human body. The compositions of the present invention when orally ingested on a daily basis, in combination with or without therapeutic treatments for diabetes, work to aid the diabetic patient in slowing or eliminating, or reversing the progression of the disease.
Although the mechanism of action of the compositions of the present invention are not well understood, many cases have been reported of diabetic patients benefiting from the use of the present invention.
It is believed that the key ingredients of the present invention work synergistically together to aid in the slowing, stopping, or reversing the symptoms and metabolic disorder characteristic of the human diabetic condition.
These compositions include as preferred essential component the mineral of chromium. The preferred form of chromium is yeast. The preferred amount of chromium yeast is from about 5 mcg to about 5000 mcg, and more preferred between about 100 meg to about 2500 mcg, and most preferably from between 1000 mcg to about 2000 mcg. The preferred chromium yeast strains are Saccharomyces cerevisiae, Saccharomyces exiguous, Saccharomyces pastorianus, Saccharomyces boulardii, Saccharomyces bayanus, Saccharomyces eubayanus, Saccharomyces florentinus, Saccharomyces fragilis.
A prime essential ingredient included in all the embodiments of the present invention is Green Barley Juice powder. The preferred form of Green Barley Juice powder is derived from organic barley and through the process of lylyophilization of the extracted juice of the organic barley. The amount of Green Barley Juice powder 500 mg to about 3500 mg, more preferably from between 750 mg to about 2000 mg, and most preferably between 800 mg to about 1500 mg.
Inulin must be included as an essential component of the present invention. The types of Inulin to be used in the present invention include short chain, medium chain, and long chain polymers of fructoligosaccharides. The preferred amount in the present invention is from about 0.5 g to about 10.0 grams, preferably between 1 g and 7.5 g, and most preferably between 2 g and 5 g.
Another essential component is Bitter Melon. The preferred amount of Bitter Melon is from about 2 mg to about 300 mg, preferably from about 50 mg to about 250 mg, and most preferably about 100 mg to about 175 mg.
Another essential component is Erythritol. The preferred amount of Erythritol is between 1 g and 30 g, most preferably between from about 2 g-14 g.
Another essential component is Fenugreek Seed. The preferred amount of Fenugreek Seed is from about 2 mg to about 200 mg, preferably from about 50 mg to about 250 mg, and most preferably about 75 mg to about 125 mg
Another essential component is Citrus Bioflavonoid. The preferred amount of Citrus Bioflavonoid is from about 2 mg to about 300 mg, preferably from about 50 mg to about 250 mg, and most preferably about 100 mg to about 175 mg
Another essential component is Lime Juice Powder. The preferred amount of Lime Juice Powder is from about 1 mg to about 100 mg, preferably from about 50 mg to about 250 mg, and most preferably about 10 mg to about 75 mg.
Another essential component is Wheat Grass Juice Powder. The preferred amount of Wheat Grass Juice Powder is from about 0.5 mg to about 500 mg, preferably from about 50 mg to about 350 mg, and most preferably about 100 mg to about 275 mg
These compositions may also include as preferred component the mineral of selenium. The preferred form of selenium is selenium yeast. The preferred amount of selenium yeast is from about 5 mcg to about 5000 mcg, and more preferred between about 100 mcg to about 2500 mcg, and most preferably from between 1000 mcg to about 2000 mcg. The preferred selenium yeast are Saccharomyces cerevisiae, Saccharomyces exiguous, Saccharomyces pastorianus, Saccharomyces boulardii, Saccharomyces bayanus, Saccharomyces eubayanus, Saccharomyces florentinus, Saccharomyces fragilis.
Another essential component of the present invention is Beta Carotene. The preferred form of beta carotene is the naturally occurring form. The preferred amount is between 10 mcg and 100 mg, and more preferably between 100 mcg and 10 mg, and most preferably between about 500 mcg and 50 mg.
Additionally, Vitamin D3 may be added to the nutritional compositions of the present invention. The preferred form of Vitamin D3 is Cholecalciferol. The preferred amount of Vitamin D3 is from between 50 iu and 3000 iu, and more preferably between from about 70 iu to about 500 iu, and most preferably from about 100 iu to about 250 iu.
Another prime nutrient that may be included in the embodiments of the present invention is Vitamin K. The preferred form of Vitamin K is Phytonadione. The preferred amount of Vitamin K is between 2.5 mcg to about 250 mcg, more preferably from between 15 mcg to about 100 mcg, and most preferably between 20 mcg to about 75 mcg.
Another nutrient important to the efficacy of the present invention is Vitamin B6. The preferred form of Vitamin B6 is Pyridoxine hydrochloride. The preferred amount is between 0.1 mg to about 100 mg, most preferably between about 0.5 mg to about 25 mg, and most preferably from about 0.75 mg to about 10 mg.
Additionally, Vitamin B12 may be included in the present invention. The preferred form of Vitamin B12 is Cyanocobalamin. The preferred amount of Vitamin B12 is between about 0.3 mcg to about 900 mcg, most preferably between about 0.75 mcg to about 50 mcg, and most preferably between 1 mcg and 10 mcg.
Another nutrient that is important to the present invention is Folic Acid. The preferred amount of Folic Acid is between about 25 mcg to about 1000 mcg, most preferably between about 100 mcg to about 750 mcg, and most preferably between 200 mcg and 400 mcg.
The mineral Zinc is important to include in the present invention. The preferred amount of Zinc is between about 0.65 mcg to about 4000 mcg, most preferably between about 1 mcg to about 400 mcg, and most preferably between 3 mcg and 50 mcg.
The mineral Molybdenum is important to include in the present invention. The preferred form of Molybdenum is from yeast. The preferred amount of Molybdenum is between about 2.5 mcg to about 1000 mcg, most preferably between about 10 mcg to about 130 mcg, and most preferably between 15 mcg and 60 mcg.
Another important nutrient is Coenzyme Q-10. The preferred amount of Coenzyme Q-10 is from about 30 mg to about 1000 mg, most preferably from between about 50 mg to 300 mg, and most preferably between about 60 mg to about 180 mg.
The following examples are illustrative only and do not limit the invention in any fashion.
Example 1
Ingredient Amount
Barley Grass Juice Powder 1250 mg
Inulin 1250 mg
Chromium (from Chromium Yeast) 50 mcg
Bitter Melon Fruit 100 mg
Fenugreek Seed 50 mg
Citrus Bioflavonoid 50 mg
Lime Juice Powder 50 mg
Wheat Grass Juice Powder 50 mg
Fish Oil 110 mg
Selenium (from Selenium yeast) 1500 mcg
Beta Carotene 200 iu
Vitamin D3 100 iu
Vitamin K 15 mcg
Vitamin B6 0.5 mg
Vitamin B12 1 mcg
Folic Acid 250 mcg
Zinc 5.0 mg
Molybdenum 15 mcg
CoQ-10 50 mg
Niacin 2.1 mg
Riboflavin 600 mcg
Thiamin 530 mcg
Biotin 2 mg
Calcium 200 mg
Iron 3 mg
Phosphourous 213 mg
Iodine 35 mg
Copper 500 mcg
Manganese 570 mcg
Inositol 1.2 g
Soy Protein 1000 mg
Whey Protein Concentrate 5000 mg
Erythritol 2500 mg
Stevia Extract 3 mg
The above ingredients were admixed as a single serving, and were blended together and shaken until homogeneous blend was obtained. The blended composition was poured into 250 mL of water, mixed and then consumed via drinking.
Example 2
Ingredient Amount
Barley Grass Juice Powder 1250 mg
Inulin 1250 mg
Chromium (from Chromium Yeast) 50 mcg
Bitter Melon Fruit 100 mg
Fenugreek Seed 50 mg
Citrus Bioflavonoid 50 mg
Lime Juice Powder 50 mg
Wheat Grass Juice Powder 50 mg
Fish Oil 110 mg
Selenium (from Selenium yeast) 1500 mcg
Beta Carotene 2000 mcg
Ascorbic Acid 75 mg
Vitamin D3 100 iu
Vitamin K 15 mcg
Vitamin B6 0.5 mg
Vitamin B12 1 mcg
Folic Acid 250 mcg
Zinc 5.3 mg
Molybdenum 15 mcg
CoQ-10 52 mg
Niacin 3.1 mg
Riboflavin 600 mcg
Thiamin 530 mcg
Biotin 2 mg
Calcium 200 mg
Iron 3 mg
Phosphourous 213 mg
Iodine 35 mg
Copper 500 mcg
Manganese 570 mcg
Inositol 1.2 g
Potassium Iodide 10 mg
Debittered Brewers Yeast 10 mg
Copper Gluconate 3 mg
Bilerry Extract 3 mg
Evening Primrose Oil 50 mg
Green Tea Extract 25 mg
Broccoli Powder 50 mg
Choline Bitartrate 75 mg
Acerola Fruit Powder 30 mg
Grape Juiece Concentrate 7 mg
Erythritol 2200 mg
Rose Hips Powder 0.5 mg
Lycopene 45 mg
Organic Oat Grass Juice Powder 35 mg
Pine Bark Extract 10 mg
Spinach Powder 35 mg
Parsely Powder 50 mg
Rutin 10 mg
Articoke Leaf 10 mg
Raspberry Fruit Powder 50 mg
Lutein 10 mg
Chlorella 10 mg
Soy Protein 1000 mg
Whey Protein Concentrate 5000 mg
Natural Spearmint Flavor 300 mg
Stevia Extract 1 mg
The above ingredients were admixed as a single serving, and were blended together and shaken until homogeneous blend was obtained. The blended composition was poured into 250 mL of water, mixed and then consumed via drinking.
Example 3
Ingredient Amount
Barley Grass Juice Powder 1050 mg
Inulin 1420 mg
Chromium (from Chromium Yeast) 75 mcg
Bitter Melon Fruit 110 mg
Fenugreek Seed 59 mg
Citrus Bioflavonoid 43 mg
Lime Juice Powder 76 mg
Wheat Grass Juice Powder 72 mg
Fish Oil 135 mg
Selenium (from Selenium yeast) 1500 mcg
Beta Carotene 300 mcg
Ascorbic Acid 85 mg
Vitamin D3 200 iu
Vitamin K 25 mcg
Vitamin B6 0.5 mg
Vitamin B12 1 mcg
Folic Acid 230 mcg
Zinc 5.8 mg
Molybdenum 17 mcg
CoQ-10 62 mg
Niacin 3.7 mg
Riboflavin 649 mcg
Thiamin 530 mcg
Biotin 3 mg
Calcium 200 mg
Iron 3 mg
Phosphourous 213 mg
Iodine 35 mg
Copper 500 mcg
Manganese 570 mcg
Inositol 1.2 g
Potassium Iodide 10 mg
Debittered Brewers Yeast 10 mg
Copper Gluconate 3 mg
Bilerry Extract 3 mg
Evening Primrose Oil 50 mg
Green Tea Extract 25 mg
Broccoli Powder 50 mg
Choline Bitartrate 75 mg
Acerola Fruit Powder 30 mg
Grape Juiece Concentrate 7 mg
Rose Hips Powder 0.5 mg
Lycopene 45 mg
Organic Oat Grass Juice Powder 35 mg
Pine Bark Extract 10 mg
Spinach Powder 35 mg
Parsely Powder 50 mg
Rutin 10 mg
Articoke Leaf 10 mg
Raspberry Fruit Powder 50 mg
Lutein 10 mg
Chlorella 10 mg
Soy Protein 1500 mg
Whey Protein Concentrate 4000 mg
Natural Orange Flavor 300 mg
Erythritol 1500 mg
Stevia extract 3 mg
The above ingredients were admixed as a single serving, and were blended together and shaken until homogeneous blend was obtained. The blended composition was poured into 250 mL of water, mixed and then consumed via drinking.
Example 4
Ingredient Amount
Barley Grass Juice Powder 1310 mg
Inulin 1600 mg
Chromium (from Chromium Yeast) 200 mcg
Bitter Melon Fruit 90 mg
Fenugreek Seed 65 mg
Citrus Bioflavonoid 1000 mg
Lime Juice Powder 1000 mg
Wheat Grass Juice Powder 1000 mg
Fish Oil 310 mg
Selenium (from Selenium yeast) 500 mcg
Beta Carotene 1200 mcg
Ascorbic Acid 95 mg
Vitamin D3 200 iu
Vitamin K 11 mcg
Vitamin B6 1.5 mg
Vitamin B12 1.1 mcg
Folic Acid 230 mcg
Zinc 5.1 mg
Molybdenum 17 mcg
CoQ-10 72 mg
Niacin 3.1 mg
Riboflavin 647 mcg
Thiamin 530 mcg
Biotin 3 mg
Calcium 200 mg
Iron 2.5 mg
Phosphourous 200 mg
Iodine 25 mg
Copper 680 mcg
Manganese 473 mcg
Inositol 1.1 g
Potassium Iodide 10 mg
Debittered Brewers Yeast 10 mg
Copper Gluconate 3 mg
Bilerry Extract 3 mg
Evening Primrose Oil 50 mg
Green Tea Extract 25 mg
Broccoli Powder 50 mg
Choline Bitartrate 75 mg
Acerola Fruit Powder 30 mg
Grape Juiece Concentrate 7 mg
Rose Hips Powder 0.5 mg
Lycopene 45 mg
Erythritol 2500 mg
Organic Oat Grass Juice Powder 35 mg
Pine Bark Extract 10 mg
Spinach Powder 35 mg
Parsely Powder 50 mg
Rutin 10 mg
Articoke Leaf 10 mg
Raspberry Fruit Powder 50 mg
Lutein 10 mg
Chlorella 10 mg
Soy Protein 1000 mg
Whey Protein Concentrate 5000 mg
Natural Spearmint Flavor 300 mg
Stevia Extract 100 mcg
The above ingredients were admixed as a single serving, and were blended together and shaken until homogeneous blend was obtained. The blended composition was poured into 250 mL of water, mixed and then consumed via drinking.
Example 5
Ingredient Amount
Barley Grass Juice Powder 2550 mg
Inulin 850 mg
Chromium (from Chromium Yeast) 1200 mcg
Bitter Melon Fruit 200 mg
Fenugreek Seed 39 mg
Citrus Bioflavonoid 80 mg
Lime Juice Powder 90 mg
Wheat Grass Juice Powder 90 mg
Fish Oil 310 mg
Selenium (from Selenium yeast) 500 mcg
Beta Carotene 100 mcg
Ascorbic Acid 500 mg
Vitamin D3 100 iu
Vitamin K 15 mcg
Vitamin B6 0.5 mg
Vitamin B12 1 mcg
Folic Acid 250 mcg
Zinc 5.3 mg
Molybdenum 15 mcg
CoQ-10 52 mg
Niacin 3.1 mg
Riboflavin 300 mcg
Thiamin 130 mcg
Erythritol 2500 mg
Biotin 1 mg
Calcium 400 mg
Iron 3 mg
Phosphourous 220 mg
Iodine 37 mg
Copper 510 mcg
Manganese 524 mcg
Inositol 1.1 g
Potassium Iodide 10 mg
Debittered Brewers Yeast 10 mg
Copper Gluconate 3 mg
Bilerry Extract 3 mg
Evening Primrose Oil 50 mg
Green Tea Extract 25 mg
Broccoli Powder 50 mg
Choline Bitartrate 75 mg
Acerola Fruit Powder 30 mg
Grape Juiece Concentrate 7 mg
Rose Hips Powder 0.5 mg
Lycopene 45 mg
Organic Oat Grass Juice Powder 35 mg
Pine Bark Extract 10 mg
Spinach Powder 35 mg
Parsely Powder 50 mg
Rutin 10 mg
Articoke Leaf 10 mg
Raspberry Fruit Powder 50 mg
Lutein 10 mg
Chlorella 10 mg
Soy Protein 1000 mg
Whey Protein Concentrate 5000 mg
Natural Spearmint Flavor 300 mg
The above ingredients were admixed as a single serving, and were blended together and shaken until homogeneous blend was obtained. The blended composition was poured into 250 mL of water, mixed and then consumed via drinking.

Claims (10)

What is claimed is:
1. A method of treatment of diabetes, the method comprising:
orally administering a nutritional composition to a diabetes patient in need thereof, the nutritional composition comprising:
5 μg to 5000 μg chromium;
500 mg to 3500 mg lyophilized barley grass juice;
0.5 g to 10.0 g isolated and purified inulin;
2 mg to 300 mg bitter melon fruit;
1 g to 30 g isolated and purified erythritol;
2 mg to 200 mg fenugreek seed;
2 mg to 300 mg isolated and purified citrus bioflavonoid;
1 mg to about 100 mg lyophilized lime juice; and
0.5 mg to about 500 mg lyophilized wheat grass juice;
wherein the nutritional composition slows, stops, or reverses symptoms characteristic of human diabetes.
2. The method of claim 1, wherein the nutritional composition further comprises 5 μg to 5000 μg selenium, wherein selenium is in the form of selenium yeast.
3. The method of claim 1, wherein the nutritional composition further comprises 10 μg to 100 μg beta carotene.
4. The method of claim 1, wherein the nutritional composition further comprises 50 iu to 3000 iu vitamin d3.
5. The method of claim 1, wherein the nutritional composition further comprises 25 μg to 250 μg vitamin k.
6. The method of claim 1, wherein the nutritional composition further comprises 0.1 mg to 100 mg vitamin B6.
7. The method of claim 1, wherein the nutritional composition further comprises 25 μg to 1000m folic acid.
8. The method of claim 1, wherein the nutritional composition further comprises 0.65 μg to 4000 μg zinc.
9. The method of claim 1, wherein the nutritional composition further comprises 25 μg to 1000 μg molybdenum.
10. The method of claim 1, wherein the nutritional composition further comprises 30 mg to 1000 mg coenzyme Q-10.
US15/355,490 2013-10-04 2016-11-18 Diabetic nutritional composition Active 2034-03-16 US10342845B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/355,490 US10342845B1 (en) 2013-10-04 2016-11-18 Diabetic nutritional composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/045,920 US9913872B2 (en) 2013-10-04 2013-10-04 Diabetic nutritional composition
US15/355,490 US10342845B1 (en) 2013-10-04 2016-11-18 Diabetic nutritional composition

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US14/045,920 Division US9913872B2 (en) 2013-10-04 2013-10-04 Diabetic nutritional composition

Publications (1)

Publication Number Publication Date
US10342845B1 true US10342845B1 (en) 2019-07-09

Family

ID=52777116

Family Applications (2)

Application Number Title Priority Date Filing Date
US14/045,920 Active 2035-05-02 US9913872B2 (en) 2013-10-04 2013-10-04 Diabetic nutritional composition
US15/355,490 Active 2034-03-16 US10342845B1 (en) 2013-10-04 2016-11-18 Diabetic nutritional composition

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US14/045,920 Active 2035-05-02 US9913872B2 (en) 2013-10-04 2013-10-04 Diabetic nutritional composition

Country Status (1)

Country Link
US (2) US9913872B2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3925612A1 (en) * 2020-06-17 2021-12-22 Lytone Enterprise, Inc. Herbal composition for reducing uric acid and its use in reducing uric acid, body fat, and blood glucose thereof

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107969506A (en) * 2017-11-29 2018-05-01 山东禹王制药有限公司 A kind of high stability fish oil breast for improving glycometabolism and preparation method thereof
CN108968043A (en) * 2018-07-02 2018-12-11 江西人之初乳品营养有限公司 A kind of composition and its application for helping to control Energy intaking and the conversion of postprandial energy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100074969A1 (en) 2008-09-19 2010-03-25 Unicity International, Inc. Method of controlling blood sugar levels, insulin levels, cholesterol levels, body fat levels, and body weight by administering a nutrient fiber matrix
US7879796B2 (en) 2005-03-21 2011-02-01 Abbott Laboratories Amino acid composition for improving glucose tolerance
US8017147B2 (en) * 2008-04-07 2011-09-13 Mazed Mohammad A Nutritional supplement for the prevention of cardiovascular disease, alzheimer's disease, diabetes, and regulation and reduction of blood sugar and insulin resistance

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7879796B2 (en) 2005-03-21 2011-02-01 Abbott Laboratories Amino acid composition for improving glucose tolerance
US8017147B2 (en) * 2008-04-07 2011-09-13 Mazed Mohammad A Nutritional supplement for the prevention of cardiovascular disease, alzheimer's disease, diabetes, and regulation and reduction of blood sugar and insulin resistance
US20100074969A1 (en) 2008-09-19 2010-03-25 Unicity International, Inc. Method of controlling blood sugar levels, insulin levels, cholesterol levels, body fat levels, and body weight by administering a nutrient fiber matrix

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Schrauzer (Pure Appl. Chem. (2006), vol. 78, No. 1, pp. 105-109). *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3925612A1 (en) * 2020-06-17 2021-12-22 Lytone Enterprise, Inc. Herbal composition for reducing uric acid and its use in reducing uric acid, body fat, and blood glucose thereof

Also Published As

Publication number Publication date
US20150098930A1 (en) 2015-04-09
US9913872B2 (en) 2018-03-13

Similar Documents

Publication Publication Date Title
US11576940B2 (en) Nutritional composition
US6572899B1 (en) Memory loss treatment formulation
US6511675B2 (en) Composition and method for correcting a dietary phytochemical deficiency
US20050266018A1 (en) Nutraceutical compositions with mangosteen
JP5084512B2 (en) Antioxidant dietary supplement compositions and methods for maintaining healthy skin
US10342845B1 (en) Diabetic nutritional composition
JP6660289B2 (en) A composition comprising a combination of an elder extract with a strain of Lactobacillus rhamnosus
JP4102820B2 (en) Dietary supplements and related methods
US20050238731A1 (en) Composition and method for treating the effects of diseases and maladies of the upper digestive tract
EP1858507B1 (en) Polyphenol coxib combinations and methods
US8197871B2 (en) Composition for headache treatment
US20220323535A1 (en) Health supplement
US11077085B2 (en) Dietary macro/micronutritional supplement for patients undergoing kidney dialysis
US10149831B1 (en) Pharmaceutical composition for treating bacterial and viral infections
US20160038530A1 (en) Nutritional Supplement to Complement Cancer Therapy
KR101010575B1 (en) The composition for the atopic dermatitis improving with vinegar
US20150147305A1 (en) Asthmatic and Allergenic Nutritional Composition
Yadav et al. Experimental evidences showing nutritional and medicinal property of Carica papaya plant
Ryan-Harshman et al. Health benefits of selected vitamins
US11504411B1 (en) Herbal dietary supplement supporting healthy immune function
RU2813786C1 (en) Tonic drink and method of its preparation
KR20190012943A (en) Health functional food composition for Burning mouth syndrome and Stomatitis Treatment and Prevention
US20180344796A1 (en) Method for treating fibromyalgia
US8889157B1 (en) Composition for cardiovascular treatment
US10166265B1 (en) Pharmaceutical composition for treating bacterial and viral infections

Legal Events

Date Code Title Description
STCF Information on status: patent grant

Free format text: PATENTED CASE

FEPP Fee payment procedure

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

FEPP Fee payment procedure

Free format text: SURCHARGE FOR LATE PAYMENT, SMALL ENTITY (ORIGINAL EVENT CODE: M2554); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2551); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

Year of fee payment: 4